Reasons for Treatment Changes in Patients With Moderate to Severe Psoriasis

被引:5
|
作者
Anderson, Kathryn L. [1 ]
Feldman, Steven R. [1 ,2 ,3 ]
机构
[1] Wake Forest Sch Med, Dept Dermatol, Ctr Dermatol Res, Winston Salem, NC 27157 USA
[2] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC 27157 USA
[3] Wake Forest Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA
关键词
psoriasis; phototherapy; dermatology; TREATMENT PATTERNS; DRUG SURVIVAL; BIOLOGICS; DISCONTINUATION; POPULATION; ETANERCEPT; ADALIMUMAB; CARE; IMPAIRMENT; THERAPIES;
D O I
10.1177/1203475415572797
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Psoriasis treatment involves multiple treatment arms. Treatment choice depends on many factors and may change, due to the chronicity of psoriasis. Objective: The purpose of our study is to explore reasons for treatment changes in patients with moderate to severe psoriasis. Methods: Ten charts of patients with moderate to severe psoriasis were reviewed. The medication changes and reasons for change were extracted. A treatment change was defined as switching between medication classes, adding or removing a medication class, or switching medications within the oral or biologic medication class. Results: Seventy-seven treatment changes were identified. On average, I treatment change occurred per year of follow-up. The most common reason for treatment change was inadequate disease control. Conclusions: Inadequate disease control with current therapy is the most common reason a physician changes treatment for moderate to severe psoriasis. More efficacious treatments or ways to improve efficacy may help improve the long-term outcomes of psoriasis.
引用
收藏
页码:361 / 366
页数:6
相关论文
共 50 条
  • [41] Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis A Phase 3 Randomized Clinical Trial
    Blauvelt, Andrew
    Leonardi, Craig L.
    Gooderham, Melinda
    Papp, Kim A.
    Philipp, Sandra
    Wu, Jashin J.
    Igarashi, Atsuyuki
    Flack, Mary
    Geng, Ziqian
    Wu, Tianshuang
    Camez, Anne
    Williams, David
    Langley, Richard G.
    JAMA DERMATOLOGY, 2020, 156 (06) : 649 - 658
  • [42] Definition of treatment goals for moderate to severe psoriasis: a European consensus
    Mrowietz, U.
    Kragballe, K.
    Reich, K.
    Spuls, P.
    Griffiths, C. E. M.
    Nast, A.
    Franke, J.
    Antoniou, C.
    Arenberger, P.
    Balieva, F.
    Bylaite, M.
    Correia, O.
    Dauden, E.
    Gisondi, P.
    Iversen, L.
    Kemeny, L.
    Lahfa, M.
    Nijsten, T.
    Rantanen, T.
    Reich, A.
    Rosenbach, T.
    Segaert, S.
    Smith, C.
    Talme, T.
    Volc-Platzer, B.
    Yawalkar, N.
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2011, 303 (01) : 1 - 10
  • [43] INFLIXIMAB BIOSIMILAR VERSUS METHOTREXATE FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS
    Sarbu, Maria-Isabela
    Tampa, Mircea
    Matei, Clara
    Mitran, Cristina-Iulia
    Mitran, Madalina-Irina
    Pituru, Silviu
    Pop, Corina Silvia
    Saramet, Gabriel
    Georgescu, Simona-Roxana
    FARMACIA, 2017, 65 (06) : 962 - 967
  • [44] Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a US commercially insured population
    Wu, Bingcao
    Muser, Erik
    Teeple, Amanda
    Pericone, Christopher D.
    Feldman, Steven R.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (06) : 595 - 602
  • [45] Use of Biologics in the Treatment of Moderate-to-Severe Plantar Psoriasis
    Ekladios, Josh
    Jolliffe, Jason
    Panchigar, Shalin
    Qureshi, Rafay
    Shete, Ankita
    Wellner, Jason
    Vlahovic, Tracey C.
    CLINICS IN PODIATRIC MEDICINE AND SURGERY, 2021, 38 (04) : 553 - 559
  • [46] What are the objectives of moderate to severe psoriasis treatment?
    Ortonne, J. -P.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2008, 135 : S281 - S284
  • [47] Disparities and barriers to the access of biologics in moderate-to-severe adult psoriasis
    Wan, Vincent
    Habibi, Alireza
    Mija, Lorena A.
    Abdi, Parsa
    Selvakumar, Rishika
    Mukovozov, Ilya
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024, 63 (10) : 1293 - 1301
  • [48] Treatment of moderate-to-severe plaque psoriasis
    Salgo, R.
    Thaci, D.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2009, 144 (06): : 701 - 711
  • [49] The use of methotrexate in treatment of moderate to severe psoriasis
    Leung, W. Y.
    Lau, K. H.
    HONG KONG JOURNAL OF DERMATOLOGY & VENEREOLOGY, 2009, 17 (01): : 13 - 19
  • [50] Tofacitinib for the treatment of moderate-to-severe psoriasis
    Chiricozzi, Andrea
    Faleri, Sara
    Saraceno, Rosita
    Bianchi, Luca
    Buonomo, Oreste
    Chimenti, Sergio
    Chimenti, Maria Sole
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (04) : 443 - 455